General information about company

Scrip code*523144
NSE Symbol*NOTLISTED
MSEI Symbol*NOTLISTED
ISIN*INE442D01010
Name of companyMEDI-CAPS LIMITED
Type of companyMain Board
Class of securityEquity
Date of start of financial year01-04-2025
Date of end of financial year31-03-2026
Date of board meeting when results were approved11-02-2026
Date on which prior intimation of the meeting for considering financial results was informed to the exchange04-02-2026
Description of presentation currencyINR
Level of roundingLakhs
Reporting TypeQuarterly
Reporting QuarterThird quarter
Nature of report standalone or consolidatedStandalone
Whether results are audited or unaudited for the quarter endedUnaudited
Whether results are audited or unaudited for the Year to date for current period ended/year endedUnaudited
Segment ReportingSingle segment
Description of single segmentREAL ESTATE
Start date and time of board meeting11-02-2026 15:00
End date and time of board meeting11-02-2026 15:50
Whether cash flow statement is applicable on company
Type of cash flow statement
Declaration of unmodified opinion or statement on impact of audit qualificationNot applicable
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter?No
No. of times funds raised during the quarter
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity?NoThere was no default on Loans and Debt Securities



Financial Results – Ind-AS

Particulars3 months/ 6 months ended (dd-mm-yyyy)Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period01-10-202501-04-2025
Date of end of reporting period31-12-202531-12-2025
Whether results are audited or unauditedUnauditedUnaudited
Nature of report standalone or consolidatedStandaloneStandalone
Part IBlue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.
1Income
Revenue from operations77.28177.24
Other income17.3249.62
Total income94.6226.86
2Expenses
(a)Cost of materials consumed00
(b)Purchases of stock-in-trade00
(c)Changes in inventories of finished goods, work-in-progress and stock-in-trade0.10.25
(d)Employee benefit expense 46.73138.29
(e)Finance costs00
(f)Depreciation, depletion and amortisation expense412.01
(g)Other Expenses
1POWER COST2.33.24
2FREIGHT EXP.00
3Other Expenses10.1252.8
Total other expenses12.4256.04
Total expenses63.25206.59
3Total profit before exceptional items and tax31.3520.27
4Exceptional items 00
5Total profit before tax31.3520.27
6Tax expense
7Current tax2.852.85
8Deferred tax00
9Total tax expenses2.852.85
10Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement00
11Net Profit Loss for the period from continuing operations28.517.42
12Profit (loss) from discontinued operations before tax00
13Tax expense of discontinued operations00
14Net profit (loss) from discontinued operation after tax00
15Share of profit (loss) of associates and joint ventures accounted for using equity method00
16Total profit (loss) for period28.517.42
17Other comprehensive income net of taxes22.6265.04
18Total Comprehensive Income for the period51.1282.46
19Total profit or loss, attributable to
Profit or loss, attributable to owners of parent
Total profit or loss, attributable to non-controlling interests
20Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent
Total comprehensive income for the period attributable to owners of parent non-controlling interests
21Details of equity share capital
Paid-up equity share capital12471247
Face value of equity share capital1010
22Reserves excluding revaluation reserve
23Earnings per share
iEarnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations0.230.14
Diluted earnings (loss) per share from continuing operations0.230.14
iiEarnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations00
Diluted earnings (loss) per share from discontinued operations00
iiiEarnings per equity share (for continuing and discontinued operations)
Basic earnings (loss) per share from continuing and discontinued operations0.230.14
Diluted earnings (loss) per share from continuing and discontinued operations0.230.14
24Debt equity ratioTextual Information( 1)
25Debt service coverage ratioTextual Information( 2)
26Interest service coverage ratioTextual Information( 3)
27Disclosure of notes on financial resultsTextual Information(4)

Text Block

Textual Information(4)NOTES:

1. The above standalone and consolidated unaudited financial results for the Quarter and Nine months ended December 31, 2025, were reviewed and recommended by the Audit Committee and approved by the Board of Directors in its meeting held on February11, 2026. The above results have been reviewed by statutory Auditors of the company in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, who have expressed an unmodified opinion. The Company's Management has exercised the necessary due diligence to ensure that the financial results provide a true and fair view of its affairs.

2. This statement has been prepared in accordance with the guidelines issued by the Securities Exchange Board of India (SEBI) and Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognized accounting practices and policies to the extent applicable.

3. The above consolidated results included the result of wholly owned subsidiary company i.e. Medgel Private Limited.

4. The Company has two reportable segments for the Consolidated Financial Statements which consists of Pharma division and Real Estate division in accordance with Ind AS-108 Operating Segment and same is enclosed with this result.

5. During this quarter the Company has generated revenue of Rs. 77.28 Lacs from sale of shops at Medi-caps Business Park.

6. The figures of the previous period / year have been re-stated/ re-grouped / re-arranged/ reclassified and / or re-casted wherever found necessary.

7. The aforesaid unaudited financial Results will be uploaded on the Company's website www.medicaps.com and will also be available on the websites of the Stock exchange i.e. www.bseindia.com for the benefit of shareholders and investors. Further, publication containing a Quick Response code and the details of the webpage where complete financial results of the Company are available, will be published in English and Hindi Newspapers with in prescribed time limit.

DATE:11/02/2026 For and on behalf of the Board of directors of PLACE: INDORE MEDI-CAPS LIMITED




ALOK K GARG
MANAGING DIRECTOR
DIN: 00274321



Other Comprehensive Income

Date of start of reporting period01-10-202501-04-2025
Date of end of reporting period31-12-202531-12-2025
Whether results are audited or unauditedUnauditedUnaudited
Nature of report standalone or consolidatedStandaloneStandalone
Other comprehensive income [Abstract]
1Amount of items that will not be reclassified to profit and loss
1Items that will not be classified to statement of profit and loss22.6265.04
Total Amount of items that will not be reclassified to profit and loss22.6265.04
2Income tax relating to items that will not be reclassified to profit or loss 0.000.00
3Amount of items that will be reclassified to profit and loss
Total Amount of items that will be reclassified to profit and loss
4Income tax relating to items that will be reclassified to profit or loss 0.000.00
5Total Other comprehensive income22.6265.04